Scientists Awarded The Albany Prize, Americas Most Distinguished Prize in Medicine, for Research Leading to Covid-19 Vaccines
September 21, 2021 - Albany, NY
Threepioneeringscientists,whosediscoveries haveled toinnovativeadvances in medicine, including the vaccines for Covid-19, were presented with the 2021 Albany Medical Center Prize in Medicine and Biomedical Research, celebrating its 20th anniversary, today during a ceremony in Albany, New York. The recipients are:
Dr. Grahams research investigated optimal immunogen structure to induce potent neutralizing responses. Dr. Karik and Dr. Weissmans research focuses on the modification of nucleic acids to develop RNA therapeutics and vaccines. As one of the breakthroughs in mRNA research their findings allowed for the rapid development of mRNA-based vaccines to address the Covid-19 pandemic.
RNA (ribonucleic acid) is a vital molecule found in human cells. Pieces of RNA are used to construct proteins inside the body so that new cells can grow. There are several different types ofRNA, including mRNA (messenger RNA), that is read by ribosomes, small protein-creating factories located inside of a human cell, to build proteins necessary for human life. mRNA is used in Covid-19 vaccines produced by Pfizer/BioNTech and Moderna. The U.S. Food and Drug Administration approved the Pfizer/BioNTech coronavirus vaccine for use in people 16 and over on August 23, 2021.
At a time when the importance of scientific achievement resounds around the world with more urgency than ever, The Albany Prize continues its long tradition of honoring the most profound and transformative discoveries in medicine and of celebrating important scientific researchers.
Since The Albany Prizes inception in 2001, the annual award of $500,000 has been granted to those who have altered and positively impacted the course of medical research. In 2020, the program paused due to the pandemic, and this year the recipients of the prize will collectively receive $1 million, double its typical amount. The Albany Prize is one of the most significant prizes in medicine and science in the United States.
I am honored and humbled to present The Albany Prize to these exceptional scientists, said Vincent P. Verdile, M.D., the Lynne and Mark Groban, M.D. 67, Distinguished Dean of Albany Medical College and Chair of The Albany Prize National Selection Committee. Collectively, The Albany Prize recipients have made major contributions to science over decades as researchers, mentors, and educators. Their years of work, scientific expertise, and sheer determination played a critical role in accelerating the development of two mRNA Covid-19 vaccines. And their dedication exemplifies The Albany Prize legacy to honor scientists whose work has demonstrated significant outcomes for the betterment of humankind.
Getting Ahead of a Pandemic
Barney S. Graham, M.D., Ph.D., an immunologist, virologist, and clinical research physician, is a pioneer in structure-based vaccine design and a thought leader on pandemic preparedness. When the genetic sequence of SARS-CoV-2 was first announced, Dr. Grahams lab, armed with years of mRNA clinical work and safety data, solved the mystery of Covid-19 with astonishing speed. Because of this success, it is expected that mRNA technology will play a vital role in the future of vaccine development.
When he began researching a concerning childhood infection, respiratory syncytial virus (RSV), nearly four decades ago, Dr. Graham, then at Vanderbilt University, had no idea that his work might someday be crucial to deliverance from a global pandemic.
Yet, two coronavirus vaccines are founded on a design developed by Dr. Graham and his colleagues.
The mRNA vaccines developed by Pfizer/BioNTech and Moderna use the discoveries by Dr. Graham and his colleagues and fellow Albany Prize recipients Katalin Karik, Ph.D.and Drew Weissman, M.D., Ph.D., both at the University of Pennsylvania.
The idea of creating a vaccine with messenger RNA, or mRNA, the substance that converts DNA into proteins, goes back decades. However, early efforts to create mRNA vaccines failed because the raw RNA was destroyed before generating the desired response.
Drs. Karik and Weissman came up with the notion that modifying an element of mRNA would enable it to slip past the immune system undetected. Along with important contributions of other scientists, the modifications Dr. Karik and Dr. Weissman discovered allowed mRNA to become a promising delivery system for both vaccines and drugs.
Another key contribution to the mRNA vaccines is thebioengineered protein developed by Dr. Graham and his collaborators. The protein design was based on the observation that so-called fusion proteins, the pieces of the virus that enable it to invade a cell, are shape-shifters, presenting different surfaces to the immune system after the virus fuses with and infects cells. Dr. Graham and his colleagues learned that antibodies against the post-fusion protein are far less effective at stopping an infection.
Dr. Grahams lab at the National Institutes of Health (NIH) started working with Moderna in 2017 to design a rapid manufacturing system for vaccines. In January 2019, they were preparing a demonstration project, a clinical trial to test whether Dr. Grahams protein design and Modernas mRNA platform could be used to create a vaccine against Nipah, a deadly virus spread by bats in Asia.
Their plans changed rapidly when they learned on January 7, 2020, that a coronavirus was causing the epidemic of respiratory disease in China.
We agreed immediately that the demonstration project would focus on this new virus instead of Nipah, Dr. Graham said. Moderna produced a vaccine within six weeks. The first patient was vaccinated in an NIH-led clinical study on March 16, 2020. The early results from Modernas 30,000-volunteer, late-stage trial showed it was nearly 95 percent effective at preventing Covid-19.
Dr. Graham is confident that carefully designed vaccines using nucleic acids reflect the future of new vaccines. Already, two major drug companies are doing advanced clinical trials for RSV vaccines based on the designs we discovered, he said.
In a larger sense, the pandemic may become the event that paves the way for better, possibly less expensive, and more plentiful vaccines.
Basic research informs everything we do, and planning and preparedness can make such a difference in how we get ahead of these epidemics, Dr. Graham said.
During his career, Dr. Grahams primary interests were viral pathogenesis, immunity, and vaccine development. Despite his retirement, his laboratory will remain focused on respiratory viral pathogens, pandemic preparedness, and emerging viral diseases. He applied structural biology, protein engineering, and other new technologies to create vaccines for unmet needs and emerging threats, advancing the principles of precision vaccinology. He was involved in the clinical evaluation of candidate vaccines for more than 30 years and has an ongoing interest in science education and expanding research opportunities for underrepresented minorities. He has led the development and testing of new vaccines for many global pathogens, including RSV, influenza, HIV, Ebola, West Nile, chikungunya, Zika, SARS, and MERS.
It is a great honor to be associated with Dr. Karik and Dr. Weissman and a privilege to be among previous Albany Prize recipients, said Dr. Graham. I am very grateful to all those who have helped me on my journey and to my early mentors for their generosity and inspiration.
PioneeringMessenger RNA Research
When she was in graduate school in the 1970s,Katalin Karik, Ph.D., learned about something that would become a career-defining obsession: Messenger RNA (mRNA).
Dr. Karik, a biochemist, believed in its enormous potential, but for decades she relentlessly explored how the single-stranded molecules of genetic code could be used to treat conditions from strokes and cancer to influenza.
In mRNA vaccine technology, synthetic mRNA is placed as a messenger in cells to oversee the appropriate protein production in the human body. It teaches the immune system to protect against new invaders. The idea is not new, but researchers could not use the mRNA without serious side effects.
Researchers began to give up on the technology, but Dr. Karik kept insisting that it could work, enduring a fair share of rejection in the scientific community.
Drs. Karik and Weissman investigated RNA-mediated immune activation, and in groundbreaking research, they discovered that nucleoside modifications suppress the immunogenicity of RNA. With the support of NIH, their team demonstrated the feasibility of using nucleoside-modified mRNA for protein replacement, thus opening a new field of therapy.
The breakthrough came when Dr. Karik and her fellow Albany Prize recipient Drew Weissman, M.D., Ph.D., an immunologist, made a critical discovery at the University of Pennsylvania. To slip synthetic mRNA past the cells defenses, they realized that they had to tweak one of its molecular building blocks, the nucleosides that comprise a strand of RNA. Their novel solution has been described as the biological equivalent of swapping out a tire; essentially, the side effects could be eliminated, opening doors to develop various new vaccines and drugs. The results were published in 2005, and patents were secured.
The founding scientists of BioNTech, established in 2008 in Mainz, Germany, understood the tremendous potential of the Karik-Weissman discovery and hired Dr. Karik in 2013 to oversee its mRNA research.
Using the new technology, BioNTech and Pfizer together developed a coronavirus vaccine. Modernas vaccine is also based on nucleoside-modified mRNA.
Im hopeful, Dr. Karik said, now that there is so much interest and excitement for research, that it will be possible to develop mRNA technology for prevention and treatment of other diseases, too.
No Rest Until the World Has Access to the Vaccine
An international leader in RNA biology, Drew Weissman, M.D., Ph.D., Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania, has a sharp focus on providing global vaccine access.
Research by Dr. Weissman and fellow Albany Prize recipient KatalinKarik, Ph.D.,laid one part of the groundwork for the mRNA vaccines for Covid-19 developed by Pfizer/BioNTech and Moderna, enabling the creation and emergency use authorization of these vaccines within nine months. Thus far,more than 370 million dosesof one of these mRNA-based Covid vaccines have been administered in the United States.
Covid-19 will continue to be a problem until at least two-thirds of the global population is vaccinated, Dr. Weissman said, calling for efforts to minimize the inequity that has left large parts of the world without access to doses.
There are two things that have to happen for us to get the pandemic under control and stop the variants from appearing. We have to vaccinate the entire world, and countries need to have a high enough percentage of people vaccinated somewhere between 75-85 percent in order to reach herd immunity. Until that happens, variants will keep appearing, he said.
Dr. Weissmans lab is working on multiple projects to help make vaccines more accessible. My lab and I personally have a big issue with equality of vaccine access. We are working with the government of Thailand to build its own vaccine. The country isnt content to wait in line to buy vaccines from another country. They will soon be able to make a Covid-19 vaccine in Thailand and supply it to several surrounding low- and middle-income countries. I am also working with World Health Organization to provide similar access in Africa, he said.
Currently, Dr. Weissmansresearchfocuses on RNA and innate immune system biology and applying these findings to vaccine research, therapeutics,and gene therapy. His lab is developing many vaccines for pathogens, including malaria, norovirus, influenza, C. difficile, HSV2, HIV, HCV, and vaccines for potential future pandemics, universal influenza, andpancoronavirus. His lab also develops mRNA delivery of proteins, including genetically deficient, therapeutic, and monoclonal antibodies.
Dr. Weissmans lab has recently developed new technologies to deliver mRNA-LNPs to specific cell types with a simple injection. The cells and organs targeted thus far include lung, heart, brain, CD4+ cells, T cells, and bone marrow stem cells.New therapies are being developed to treat genetic and other disorders for diseases, such as sickle cell anemia.
***
The Albany Medical Center Prize in Medicine and Biomedical Research, celebrating its 20th anniversary, was established in 2000 by the late Morris Marty Silverman, a New York City businessman and philanthropist raised in Troy, N.Y., to honor scientists whose work has demonstrated significant outcomes that offer medical value of national or international importance. A $50 million gift commitment from the Marty and Dorothy Silverman Foundation provides for the prize to be awarded annually for 100 years.
Three previous Nobel Prize winners have been among the ranks of researchers honored, and eight Albany Prize recipients have gone on to win the Nobel Prize, including James P. Allison, Ph.D., for his development of immune checkpoint blockade to treat cancer; Shinya Yamanaka, M.D., Ph.D., a leading stem cell scientist; Elizabeth Blackburn, Ph.D., who discovered the molecular nature of telomeres; Bruce Beutler, M.D., and the late Ralph Steinman, M.D., for their discoveries regarding the detailed workings of the immune system; Robert Lefkowitz, M.D., for his work on cell receptors; and Emmanuelle Charpentier, Ph.D., and Jennifer Doudna, Ph.D., for development of a method of genome editing.
For biographies and downloadable photos of the 2021 recipients and more information on The Albany Medical Center Prize in Medicine and Biomedical Research, visit: http://www.amc.edu/TheAlbanyPrize
Media Inquiries:
Sue Ford Rajchel
(518) 262 - 3421
Read the rest here:
- Drug Prototype Promising in Treatment of Pulmonary Disease - Medscape - April 20th, 2024
- Man Paralyzed In Surfing Accident Regains Ability to Walk After Stem Cell Treatment - The Inertia - April 20th, 2024
- Medical breakthrough: 8-year-old boy first in New York to receive FDA-approved gene therapy for rare inherited blood disorder - WABC-TV - April 20th, 2024
- Stem Cell Treatment Helped A Man Who Was Paralyzed From The Neck Down To Stand On His Own - Bored Panda - April 20th, 2024
- UM, CUHK jointly hold symposium on stem cells and regenerative medicine - gcs.gov.mo - April 20th, 2024
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
- Regenerative Medicine Market Size to Worth USD 95 Billion by 2032 - InvestorsObserver - February 18th, 2024
- North America Organoids Market Projected to Reach US$ 5.35 Billion by 2030, Riding on a CAGR of 21.5% - GlobeNewswire - February 18th, 2024
- Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post - February 15th, 2024
- Why leukemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatment - Medical Xpress - February 15th, 2024
- Regenerative Medicine Market is Expected to Reach $49.0 Billion | MarketsandMarkets - Yahoo Finance - February 15th, 2024
- Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells - News-Medical.Net - February 15th, 2024
- Oldest Patient 'Cured' of HIV Still in Remission 5 Years After Transplant for AML - Medpage Today - February 15th, 2024
- Drug used for cocaine addiction may pave way for new treatment of advanced colon cancer - EurekAlert - February 15th, 2024
Recent Comments